ArticleOpen veterinary journal2026
Nano-formulated curcumin restores hypothalamic-pituitary-ovarian axis disturbance in cadmium-induced female reproductive toxicity.
Article in Open veterinary journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cadmium (Cd) is a pervasive environmental toxicant associated with female reproductive dysfunction through endocrine disruption and oxidative stress. Strategies that enhance antioxidant bioavailability may improve therapeutic efficacy against heavy metal-induced ovarian damage. Aim: To investigate the protective efficacy of polycaprolactone/polyvinyl alcohol-loaded curcumin nanoparticles (PCL/PVA/Cm NPs) against CdCl₂-induced reproductive toxicity in female rats, focusing on hormonal modulation and hypothalamic-pituitary-ovarian axis gene expression. Methods: Forty-eight adult female rats were allocated into six groups: control, CdCl₂, Cm, CdCl₂ + Cm, PCL/PVA/Cm NPs, and CdCl₂+PCL/PVA/Cm NPs. Body and reproductive organ weight, Serum gonadotropin-releasing hormone (GnRH), follicle stimulating-hormone (FSH), luteinizing hormone (LH), estradiol, progesterone, and prolactin (PRL) levels were assessed after 4 weeks. Ovarian (LHR, FSHR, and aromatase) and pituitary (LHβ, FSHβ, CYP450, and PRL) gene expression levels were quantified. Results: The results revealed that CdCl₂ exposure significantly reduced body, ovarian, and uterine weights and suppressed GnRH, FSH, LH, estradiol, and progesterone levels while elevating PRL levels. Ovarian and pituitary reproductive gene expression was markedly downregulated. Cm partially reversed these effects; however, nanoformulated Cm produced significantly greater restoration, normalizing hormonal profiles and gene expression patterns to near-control values. Conclusion: The nano-encapsulation markedly enhances Cm bioefficacy, effectively restoring endocrine balance and molecular signaling within the reproductive axis. PCL/PVA/Cm NPs represent a promising nanotherapeutic strategy for mitigating Cd-induced female reproductive toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.